Overview

Artificial Tears Market is estimated to value over USD 3.7 billion by 2027 end with a CAGR of over 5.5% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Artificial Tears Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Artificial Tears Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Artificial Tears Market:
• Allergan plc
• Ocusoft Inc
• Alcon Inc.
• Novartis International AG
• Johnson & Johnson
• Abbott Medical Optics Inc.
• Santen Pharmaceuticals
• Bausch & Lomb
• McNEIL-PPC, Inc
• Carl Zeiss AG
• Advanced Vision Research, Inc
• Akron Inc
• Aura lab Ltd
• Ursapharm
• Rohto
• Similasan Corporation
(Note: The list of the major players will be updated with the latest market scenario and trends)

Artificial Tears Market Segmentation:
By Product Type
• Cellulose-derived Tears
• Glycerin-derived Tears
• Oil-based Emulsion Tears
• Polyethylene Glycol
• Propylene Glycol-based Tears
By Delivery Method 
• Eye Drops
• Ointments
By Application 
• Dry Eyes Treatment
• Contact Lenses Moisture
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Artificial Tears Market By Product Type, By Delivery Method, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Targeted Antigen launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1 Objectives of the Study 
   1.2 Market Definition 
   1.3 Market Scope 
       1.3.1 Years Considered for the Study
       1.3.2 Market Covered
   1.4 Currency 
   1.5 Limitations 
   1.6 Stakeholders 

2. Research Methodology 
    2.1 Research Data 
        2.1.1 Secondary Data
              2.1.1.1 Key Data from Secondary Sources
        2.1.2 Primary Data
              2.1.2.1 Key Data from Primary Sources
    2.2 Market Size Estimation 
    2.3 Market Breakdown and Data Triangulation 
    2.4 Assumptions for the Study  

3. Executive Summary
   3.1 Market Outlook
   3.2 Segment Outlook
   3.3 Competitive Insights

4. Global Artificial Tears Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Artificial Tears Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Artificial Tears Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Artificial Tears Market, By Product Type Historical Analysis and Forecast 2020-2027 (USD Million)
   7.1. Cellulose-derived Tears
   7.2. Glycerin-derived Tears
   7.3. Oil-based Emulsion Tears
   7.4. Polyethylene Glycol
   7.5. Propylene Glycol-based Tears
 
8. Global Artificial Tears Market, By Delivery Method Historical Analysis and Forecast 2020-2027 (USD Million)  
   8.1. Eye Drops
   8.2. Ointments
 
9. Global Artificial Tears Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)  
   9.1. Dry Eyes Treatment
   9.2. Contact Lenses Moisture
  
10. North America Artificial Tears Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
        10.2.1. U.S.A
        10.2.2. Canada
        10.2.3. Mexico
   10.3. Market Size (USD Million) Forecast for North America 2020-2027

11. Latin America Artificial Tears Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2020-2027

12. Europe Artificial Tears Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2020-2027

13. Asia Pacific Artificial Tears Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          14.2.1. Saudi Arabia
          14.2.2. UAE
          14.2.3. South Africa
          14.2.4. Egypt
    14.3. Market Size (USD Million) Forecast for MEA 2020-2027

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4.  North America - Market Share Analysis and Key Regional Players
    15.5.  Europe - Market Share Analysis and Key Regional Players
    15.6.  Asia Pacific - Market Share Analysis and Key Regional Players
    15.7.  Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Targeted Antigens Offered and Financial Layouts)
    16.1. Allergan plc
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Ocusoft Inc
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Alcon Inc.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Novartis International AG
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Johnson & Johnson
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Abbott Medical Optics Inc.
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview      
    16.7. Santen Pharmaceuticals
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Bausch & Lomb
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. McNEIL-PPC, Inc
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview 
    16.10. Carl Zeiss AG
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview 
    16.11. Advanced Vision Research, Inc
          16.11.1. Company Overview
          16.11.2. Product Portfolio
          16.11.3. SWOT Analysis
          16.11.4. Financial Overview
          16.11.5. Strategic Overview 
    16.12. Akron Inc
          16.12.1. Company Overview
          16.12.2. Product Portfolio
          16.12.3. SWOT Analysis
          16.12.4. Financial Overview
          16.12.5. Strategic Overview 
    16.13. Aura lab Ltd
          16.13.1. Company Overview
          16.13.2. Product Portfolio
          16.13.3. SWOT Analysis
          16.13.4. Financial Overview
          16.13.5. Strategic Overview 
    16.14. Ursapharm
          16.14.1. Company Overview
          16.14.2. Product Portfolio
          16.14.3. SWOT Analysis
          16.14.4. Financial Overview
          16.14.5. Strategic Overview 
    16.15. Rohto
          16.15.1. Company Overview
          16.15.2. Product Portfolio
          16.15.3. SWOT Analysis
          16.15.4. Financial Overview
          16.15.5. Strategic Overview
    16.16. Similasan Corporation
          16.16.1. Company Overview
          16.16.2. Product Portfolio
          16.16.3. SWOT Analysis
          16.16.4. Financial Overview
          16.16.5. Strategic Overview 
  
17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures